NASDAQ · NNNN
Anbio Biotechnology financials
$6.16+1.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $8.6M |
| Gross profit | $7.5M |
| Gross margin | 87.2% |
| Operating income | $5.8M |
| Net income | $6.4M |
| Net margin | 74.1% |
| Diluted EPS | $0.15 |
| EBITDA | $5.8M |
| Operating cash flow | -$6.7M |
| Free cash flow | -$6.7M |
| Diluted shares | 43.7M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $7.8M |
| Short-term investments | $4.1M |
| Total debt | $0.00 |
| Total assets | $30.2M |
| Total liabilities | $87.8K |
| Shareholders' equity | $30.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology